Literature DB >> 22973019

Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas.

Steve Scully1, Ralph Francescone, Michael Faibish, Brooke Bentley, Sherry L Taylor, Dennis Oh, Robert Schapiro, Luis Moral, Wei Yan, Rong Shao.   

Abstract

Recent evidence has shown that glioblastoma stem-like cells (GSCs) can transdifferentiate into endothelial cells and vascular-like tumor cells. The latter pattern of vascularization indicates an alternative microvascular circulation known as vasculogenic mimicry (VM). However, it remains to be clarified how the GSC-driven VM makes a significant contribution to tumor vasculature. Here, we investigated 11 cases of glioblastomas and found that most of them consisted of blood-perfused vascular channels that coexpress mural cell markers smooth muscle α-actin and platelet-derived growth factor receptor β, epidermal growth factor receptor, and vascular endothelial growth factor receptor 2 (Flk-1), but not CD31 or VE-cadherin. This microvasculature coexisted with endothelial cell-associated vessels. GSCs derived from patients with glioblastomas developed vigorous mural cell-associated vascular channels but few endothelial cell vessels in orthotopic animal models. Suppression of Flk-1 activity and gene expression abrogated GSC transdifferentiation and vascularization in vitro, and inhibited VM in animal models. This study establishes mural-like tumor cells differentiated from GSCs as a significant contributor to microvasculature of glioblastoma and points to Flk-1 as a potential target for therapeutic intervention that could complement current anti-angiogenic treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22973019      PMCID: PMC3461581          DOI: 10.1523/JNEUROSCI.2017-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  42 in total

1.  PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.

Authors:  Hongwu Zheng; Haoqiang Ying; Ruprecht Wiedemeyer; Haiyan Yan; Steven N Quayle; Elena V Ivanova; Ji-Hye Paik; Hailei Zhang; Yonghong Xiao; Samuel R Perry; Jian Hu; Anant Vinjamoori; Boyi Gan; Ergun Sahin; Milan G Chheda; Cameron Brennan; Y Alan Wang; William C Hahn; Lynda Chin; Ronald A DePinho
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

2.  A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.

Authors:  Ruihuan Chen; Merry C Nishimura; Stephanie M Bumbaca; Samir Kharbanda; William F Forrest; Ian M Kasman; Joan M Greve; Robert H Soriano; Laurie L Gilmour; Celina Sanchez Rivers; Zora Modrusan; Serban Nacu; Steve Guerrero; Kyle A Edgar; Jeffrey J Wallin; Katrin Lamszus; Manfred Westphal; Susanne Heim; C David James; Scott R VandenBerg; Joseph F Costello; Scott Moorefield; Cynthia J Cowdrey; Michael Prados; Heidi S Phillips
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

3.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Authors:  Mitomu Kioi; Hannes Vogel; Geoffrey Schultz; Robert M Hoffman; Griffith R Harsh; J Martin Brown
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

4.  Induction and isolation of vascular cells from human induced pluripotent stem cells--brief report.

Authors:  Daisuke Taura; Masakatsu Sone; Koichiro Homma; Naofumi Oyamada; Kazutoshi Takahashi; Naohisa Tamura; Shinya Yamanaka; Kazuwa Nakao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-05-07       Impact factor: 8.311

5.  GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition.

Authors:  Wei Yan; Qing Jackie Cao; Richard B Arenas; Brooke Bentley; Rong Shao
Journal:  J Biol Chem       Date:  2010-02-26       Impact factor: 5.157

6.  A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry.

Authors:  Soufiane El Hallani; Blandine Boisselier; Florent Peglion; Audrey Rousseau; Carole Colin; Ahmed Idbaih; Yannick Marie; Karima Mokhtari; Jean-Léon Thomas; Anne Eichmann; Jean-Yves Delattre; Andrew J Maniotis; Marc Sanson
Journal:  Brain       Date:  2010-04       Impact factor: 13.501

7.  Glioma cell populations grouped by different cell type markers drive brain tumor growth.

Authors:  Lars Prestegarden; Agnete Svendsen; Jian Wang; Linda Sleire; Kai Ove Skaftnesmo; Rolf Bjerkvig; Tao Yan; Lasse Askland; Andreas Persson; Per Øystein Sakariassen; Per Øyvind Enger
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

Review 8.  Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

Authors:  Joost J C Verhoeff; Olaf van Tellingen; An Claes; Lukas J A Stalpers; Myra E van Linde; Dirk J Richel; William P J Leenders; Wouter R van Furth
Journal:  BMC Cancer       Date:  2009-12-16       Impact factor: 4.430

9.  Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

Authors:  Walid S Kamoun; Carsten D Ley; Christian T Farrar; Annique M Duyverman; Johanna Lahdenranta; Delphine A Lacorre; Tracy T Batchelor; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Dai Fukumura; A Gregory Sorensen; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

10.  YKL-40, a secreted glycoprotein, promotes tumor angiogenesis.

Authors:  R Shao; K Hamel; L Petersen; Q J Cao; R B Arenas; C Bigelow; B Bentley; W Yan
Journal:  Oncogene       Date:  2009-09-21       Impact factor: 9.867

View more
  68 in total

1.  Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas: a Histologic Study.

Authors:  Joseph Di Michele; Fabio Rotondo; Kalman Kovacs; Luis V Syro; George M Yousef; Michael D Cusimano; Antonio Di Ieva
Journal:  Pathol Oncol Res       Date:  2017-01-13       Impact factor: 3.201

Review 2.  Use of bevacizumab in recurrent glioblastoma.

Authors:  Ashley Ghiaseddin; Katherine B Peters
Journal:  CNS Oncol       Date:  2015-04-23

Review 3.  Salting the Soil: Targeting the Microenvironment of Brain Metastases.

Authors:  Ethan S Srinivasan; Aaron C Tan; Carey K Anders; Ann Marie Pendergast; Dorothy A Sipkins; David M Ashley; Peter E Fecci; Mustafa Khasraw
Journal:  Mol Cancer Ther       Date:  2021-01-05       Impact factor: 6.261

Review 4.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

5.  Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma.

Authors:  Rong Shao; Ralph Francescone; Nipaporn Ngernyuang; Brooke Bentley; Sherry L Taylor; Luis Moral; Wei Yan
Journal:  Carcinogenesis       Date:  2013-11-26       Impact factor: 4.944

Review 6.  Brain mesenchymal stem cells: The other stem cells of the brain?

Authors:  Florence Appaix; Marie-France Nissou; Boudewijn van der Sanden; Matthieu Dreyfus; François Berger; Jean-Paul Issartel; Didier Wion
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

7.  Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma.

Authors:  Caroline I Schnegg; Moon Hee Yang; Subrata K Ghosh; Mei-Yu Hsu
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

Review 8.  Mouse models for studying angiogenesis and lymphangiogenesis in cancer.

Authors:  Lauri Eklund; Maija Bry; Kari Alitalo
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

9.  The Pituitary Tumors and Their Tumor-Specific Microenvironment.

Authors:  M M Kameda-Smith; J -Q Lu
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  Angiogenesis and angiogenic tyrosine kinase receptor expression in pediatric brain tumors.

Authors:  József Virág; István Kenessey; Christine Haberler; Violetta Piurkó; Katalin Bálint; Balázs Döme; József Tímár; Miklós Garami; Balázs Hegedűs
Journal:  Pathol Oncol Res       Date:  2013-11-05       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.